[ad_1]
The company is developing the first oral antiviral drug to treat one of the most common viral infections in children and adult transplant patients
Orthogon Therapeutics LLC is a drug development company focused on designing innovative antiviral drugs and anti-infective therapies. The company announced that it has raised $8 million in funding from the leading consortium of Medical Angels in the United States to advance its first-class drug asset pipeline. This financing brings the company’s total investment to date to $12.5 million.
Dr. Ali H. Munawar, CEO of Orthogon Therapeutics and former founding CEO of Novira Therapeutics, said: “Orthogon is committed to advancing the first oral antiviral drug to treat BK virus infection. “Our mission is to develop a… A safe and effective prevention and treatment option.
The full story on Benzinga.com
[ad_2]
Source link
